Ah, yes. Reports of gloom and doom. Despair. Pain! Slaughter!! They say, "No one will travel in the future economy!" Yet, ABNB posts its best quarter ever and still expects double digit growth ...so I want to thank Mr. Market for his pessimism. More pain may come, but I bought today.$Airbnb, Inc.(ABNB)$

With earnings coming out in 5 weeks, I imagine a lot of buying is taking place. Get in now because Facebook will be up 35% next year.$Meta Platforms, Inc.(FB)$

Hong Kong’s underperforming stocks will likely rebound in 2022, with a border reopening with mainland China to benefit (((gaming))))and retail shares while rising yields hold banks up $TENCENT(00700)$

The thing about GRAB that really sucks is that the premium in the call options have dried up. Non existent. $Grab Holdings(GRAB)$

Absolutely no point in holding this. There’s a reason it’s called a “meme trade” lmfao. I love watching longs painfully convince themselves that this stock holds value. Good luck with ur losses.$AMC Entertainment(AMC)$

Once upon a time Apple and Disney had almost identical share prices. Now, Apple is ahead by nearly $25 per......oh, and Apple split into 4 shares for every 1 since the start of this story...$Walt Disney(DIS)$ $Apple(AAPL)$

UBS analyst Colin Bristow placed a buy rating on Pfizer's stock and boosted his share price forecast from $52 to $60. Bristow estimates that the pharmaceutical titan will earn at least $14 billion in sales from its new oral antiviral treatment, Paxlovid. The pill has been shown to reduce the risk of hospitalization or death in high-risk patients with COVID-19 by nearly 90% in clinical trials. All told, Bristow sees Pfizer earning as much as $50 billion in sales from COVID-19 vaccines and treatments in 2022. investors applauded Pfizer's acquisition of Arena Pharmaceuticals (NASDAQ:ARNA). Mizuho analyst Vamil Divan lifted his price target on Pfizer's stock from $44 to $56 after news of the deal broke. Divan views the purchase of Arena as an intelligent way for Pfizer to diversify its produc

iPhone demand outstripping supply, Glasses set for 2022 debut, maintained Outperform. Apple store checks, supply chain data, and iPhone order delays all confirm my bullish view that currently demand is outstripping supply for iPhones 13 by roughly 10 million units globally. iPhone 13 checks continue to be much stronger than expected, with belief that Apple is now on pace to sell north of 40 million iPhones during the holiday season despite the chip shortage headwinds.$Apple(AAPL)$

Folks, we are getting a gift at these levels , buy and double your profits in 6 months. Amazing growth in this company and it will continue throughout 2022. Higher interest rates will not affect this company, it will only help as consumers will need the best rates and banks will need better data on providing loans.$Upstart Holdings, Inc.(UPST)$

The YouTube dispute was a big overhang on the stock. Resolution helps in many ways. Now, time to resume the journey. Better days ahead!$Roku Inc(ROKU)$

Dear NVAX Executive Team: Once you start to come out with a barrage of great news, you need to consider 1:6 share split in order to slow down the constant SP manipulation by institutional shareholders and shorts.  Otherwise, we will keep witnessing the constant SP manipulations.To Real Longs, please note that I gave examples of different SP levels. Regardless of which SP the management ends up issuing share split, the point is, it needs to be done at some time in the near future, and hopefully soon.What a 1:6 share split would do for Novavax.  I used today's closing for the first example.Novavax has 74mil shares in issue, while Moderna has 401mil shares in issue for a ratio of 5.4 Moderna shares for every Novavax share. Optics is a fact of life. It's not always rational

Canceling patent protections for PFE's vaccine would do nothing because Bourla reportedly said that no company has the scientific talent and production capacity to produce the vaccine. He also said it could take up to three years for a pharma to develop that capacity. Don’t try to time Pfizer , just keep on buying , it a great company with more up side .$Pfizer(PFE)$

This Citadel bomb just exploded. They are putting a hold on their clients cash till March. They are burning through so much cash to short AMC they are running low on funds. Now their clients will be lawyering up big time. This is huge for us! Becoming MOASS reality very quick. AMC is bac in the hood$AMC Entertainment(AMC)$ $Citadel Exploration, Inc.(COIL)$ $Robinhood Markets, Inc.(HOOD)$

The whole market is on pins and needles so therefore no AH action here. But what I like is that we needed to defend the $200 line and I think this ER gave us enough ammunition to call $200 as the bottom. I don’t think a report like this will allow CRWD to go below $200. And if it does, I’m buying.$CrowdStrike Holdings, Inc.(CRWD)$

This already came down quite a bit on virus and fed fear. NVDA overall is a good company. Timing issue when to jump in.$NVIDIA Corp(NVDA)$

let us do a totally fair comparison then. First let us look at revenue fair comparison: For every $100 invested in Facebook, Facebook made $13 of revenues in a year. For every $100 invested in Snowflake, Snowflake only made $0.9 of revenues in a year. Now can you see how tiny SNOW revenues are? Even if SNOW grows that tiny revenue by 100% in the next year, it will still be tiny $1.8 of revenue next year. It will still be nowhere nearly as good as Facebook even if we assume Facebook has no more revenue growth. SNOW has to keep doing 100% revenue growth rates for 4 more years just for SNOW to be as good as Facebook from revenue point of view. But as I stated earlier, SNOW cannot keep its high growth rates any longer. SNOW next quarter product sales guidance is only $345 million to $350 milli

seeing so many new bears here you know that the bottom is near. everytime I see posts like "going to 2 , fair value 4, could be 1" from bears I feel assured to buy. one thing will never change, bears only come out in hordes after sharp declines and think it will go on, these people are the best contraindicators in the markets.$Grab Holdings WTS 2026/01/12 11.5C(GRABW)$

Problem is ARK did great playing musical chairs. They pushed up the pps early last year by constantly by more shares of the companies they already owned. They got more and more money coming as their returns looked great. But in mid February when they stopped buying those shares they started to falter. Then people realized that many of their picks had little to no revenue or profits. Perhaps, in 5 years some will do great but many might be out of business. Then people who understood the fame started shorting ARK stock picks and the chair collapsed as everyone could see that many were just hyped up on a tech idea that may or may not ever work out. I sold out early but hung on to many ARK stocks I bought myself. A very bad move that has cost me. The market doesn't look good for at least the

I think Tesla is worth what it is because of Elon Musk being the CEO. If it were any other person running the company, it probably wouldn't be worth half of the current value, if that much. Apple will never be valued as Tesla is valued, not even with an AppleCar. I'm fairly certain Wall Street believes Apple is already overvalued right now because they seem to base Apple's value on its historic value and that aspect doesn't seem to change. I'm certain Apple would have to double its revenue to double the share price to reach a $5T market cap. I can't imagine any higher market cap than $5T so I have nothing to say about anything above that. It's also hard to imagine Apple having a P/E higher than 35, so I don't expect it to happen. It's just my personal opinion at this point and not written

Nio Is a Strong Buy as Its Business Evolves and Capacity Grows NIO stock traded contrary to good news in 2021, but fundamentals are set for a 2022 rally Two years ago, Chinese electrical vehicle (EV) maker Nio (NYSE:NIO) announced it didn’t have the funds to last another 12 months. Now, NIO stock is a strong-buy rated EV trade with massive upside potential going into December. Plus, the latest news and upcoming events point to an eventful 2022 for the company.$NIO Inc.(NIO)$